Semaglutide vs. Tirzepatide: Which GLP-1 Is Right for You?

If you've been researching GLP-1 medications, you've almost certainly encountered both semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). Both produce meaningful weight loss. Both are weekly injections. Both have transformed what's achievable in metabolic medicine.

But they're not the same medication, and the differences matter when it comes to choosing the right protocol for a specific patient.

The Core Difference: One Receptor vs. Two

Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a gut hormone that regulates appetite, slows gastric emptying, and improves insulin secretion.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. GIP is a second gut hormone that works synergistically with GLP-1 to regulate appetite and metabolism.

This dual mechanism is why tirzepatide tends to produce greater weight loss than semaglutide in head-to-head comparisons. More receptor activation means a stronger metabolic signal.

What the Clinical Data Shows

Semaglutide (at the 2.4 mg weekly dose used for weight management) produces average weight loss of approximately 15 percent of body weight over 68 weeks in clinical trials. This was a landmark result when it was first published — significantly better than anything previously available.

Tirzepatide (at the 15 mg maximum dose) produces average weight loss of approximately 20 to 22 percent of body weight over 72 weeks. At the highest doses, roughly 1 in 3 patients loses 25 percent or more of their body weight — results that approach what's achievable with bariatric surgery.

In the SURMOUNT-5 trial, which directly compared the two medications, tirzepatide produced approximately 47 percent more weight loss than semaglutide over 72 weeks.

Side Effect Profiles

Both medications share a similar side effect profile — nausea, constipation, and reduced appetite are the most common — because both activate the GLP-1 receptor. The differences are in degree and pattern.

Semaglutide tends to produce more pronounced nausea in some patients, particularly during dose escalation. For patients who are highly sensitive to GI side effects, the slower titration schedule available with semaglutide can be an advantage.

Tirzepatide is generally well-tolerated, with nausea rates similar to or slightly lower than semaglutide in clinical trials despite producing greater weight loss. The addition of GIP receptor activation appears to moderate some of the GI effects of GLP-1 agonism.

Who Tends to Do Better on Each

Tirzepatide is typically the first choice for patients with:

• Significant weight loss goals (30+ pounds)
• Insulin resistance or type 2 diabetes (the dual mechanism produces superior glycemic control)
• A history of tolerating GLP-1 medications well
• Desire for the most potent available option

Semaglutide may be preferred for patients with:

• Moderate weight loss goals
• A history of GI sensitivity who want a more gradual titration
• Specific clinical situations where semaglutide's longer evidence base is relevant
• Cost or access considerations (semaglutide has been available longer and compounded versions are more widely accessible in some markets)

The In-Person Requirement

At Addison Metabolic, we require an in-person evaluation before starting either medication. This isn't bureaucratic — it's clinical. The choice between semaglutide and tirzepatide, the starting dose, the titration schedule, and the monitoring protocol all depend on your specific labs, health history, and goals.

Telehealth prescribing of GLP-1 medications without baseline labs or ongoing monitoring is a genuine patient safety concern. These are powerful medications that produce significant physiological changes. They deserve the same level of clinical oversight as any other serious medical intervention.

The Bottom Line

For most patients seeking significant, sustained weight loss, tirzepatide is currently the more effective option. But "more effective on average" doesn't mean "right for every patient." The best GLP-1 medication is the one that fits your clinical picture, your tolerance, and your goals — determined through a proper evaluation, not a questionnaire.

If you're trying to decide between the two, the most useful next step is a consultation. We'll look at your labs, discuss your history, and give you a direct recommendation.